The Swiss regulatory authority said Wednesday that data submitted by AstraZeneca were not sufficient for it to authorise use of the Anglo-Swedish firm's Covid vaccine, saying "new studies" were needed. "The data currently available do not point to a positive decision regarding benefits and risks," Swissmedic said in a statement. "To obtain a conclusive assessment, the applicant will among other things have to submit additional efficacy data from a Phase III trial under way in North and South America, and these will have to be analysed." nl/rjm/spm